Trulieve Cannabis (NYSE:TRLV) Issues Earnings Results

Trulieve Cannabis (NYSE:TRLV) posted its quarterly earnings data on Friday. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.06 by $0.05, Zacks reports. The firm had revenue of $271.00 million during the quarter, compared to analysts’ expectations of $268.82 million.

Here are the key takeaways from Trulieve Cannabis’ conference call:

• Core profitability and cash flow remained strong: Medical-only revenue rose 4% sequentially to $222 million, with a 63% gross margin and $98 million of adjusted EBITDA at a 36% margin. Operating cash flow was $53 million, while quarter-end cash totaled $325 million versus $289 million of debt.
• Georgia is emerging as a significant growth driver: Expanded qualifying conditions and product formats drove a sharp increase in traffic, while patient enrollment surpassed 45,000. Trulieve is expanding cultivation, adding dispensaries, and supplying nearly 20 independent pharmacies, although temporary flower shortages constrained sales.
• Texas offers substantial expansion potential: Trulieve is converting its conditional license to final approval and has completed initial production construction. Management sees considerable upside as the program expands beyond 157,000 patients, with plans to scale production and retail locations alongside demand.
• Reported results and full-year cash-flow guidance were affected by the Harvest deconsolidation: The company posted a $406 million GAAP net loss, including a $407 million impact from the transaction, although adjusted results would have shown $20 million of net income. Full-year operating cash-flow guidance was reduced to at least $225 million, while capital-expenditure guidance increased to $95 million as Trulieve invests in growth.

Trulieve Cannabis Price Performance

NYSE TRLV traded down $0.24 on Friday, hitting $8.76. 1,039,210 shares of the stock traded hands, compared to its average volume of 811,495. Trulieve Cannabis has a 12 month low of $4.62 and a 12 month high of $13.28.

Wall Street Analyst Weigh In

TRLV has been the topic of a number of research analyst reports. Weiss Ratings started coverage on Trulieve Cannabis in a research note on Tuesday, June 16th. They issued a “sell (d-)” rating on the stock. Zacks Research raised Trulieve Cannabis to a “hold” rating in a research report on Thursday, June 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 price objective on shares of Trulieve Cannabis in a research note on Friday. Finally, Wall Street Zen lowered Trulieve Cannabis from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Trulieve Cannabis presently has an average rating of “Hold” and a consensus price target of $15.00.

Insider Activity

In other news, CEO Kim A. Rivers sold 136,811 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $8.76, for a total transaction of $1,198,464.36. Following the transaction, the chief executive officer owned 1,476,913 shares of the company’s stock, valued at $12,937,757.88. This represents a 8.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 1,699,007 shares of company stock valued at $14,661,355 in the last 90 days. Insiders own 3.79% of the company’s stock.

Trending Headlines about Trulieve Cannabis

Here are the key news stories impacting Trulieve Cannabis this week:

• Positive Sentiment: Q2 earnings beat expectations: Trulieve reported adjusted EPS of $0.11 versus the $0.06 consensus estimate, while revenue reached $271 million, exceeding expectations of $268.82 million. Trulieve Reports Second Quarter 2026 Results
• Positive Sentiment: Strong profitability and cash generation: The company reported a 60% gross margin, $109 million in operating cash flow, and $74 million in free cash flow during the first half of 2026. These results support Trulieve’s balance-sheet flexibility and ability to fund operations. Trulieve Q2 Earnings Snapshot
• Positive Sentiment: Cantor Fitzgerald maintained an Overweight rating and set a $15 price target, implying substantial upside from the recent trading level. This indicates continued analyst confidence in Trulieve’s growth and earnings outlook. Benzinga analyst rating report
• Neutral Sentiment: Investors are monitoring key signals: Recent coverage highlights operational, financial, and market indicators that could influence Trulieve’s future performance following the earnings release. Trulieve Cannabis Update: Key Signals to Watch
• Negative Sentiment: Wall Street Zen downgraded Trulieve to “Hold.” The more cautious rating may be limiting the market’s reaction to the earnings beat and contributing to recent weakness in the shares. Trulieve Cannabis Rating Lowered to Hold

About Trulieve Cannabis

Trulieve Cannabis Corp. is a vertically integrated cannabis company focused on the cultivation, processing, and retail sale of medical and adult-use cannabis products. The company offers a range of products that may include flower, pre-rolls, concentrates, edibles, vape products, and topicals through its dispensary network and branded product portfolio.

Trulieve’s operations have been centered primarily in the United States, with a strong presence in Florida and additional markets in other states where cannabis is legally regulated.